SGLT2 Inhibitors to Control Glycemia in Type 2 Diabetes Mellitus: A New Approach to an Old Problem

References

• . Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94(3):311–321
   PubMed Web of Science ®Google Scholar
• . Braga MF, Casanova A, Teoh H, ; Diabetes Registry to Improve Vascular Events [DRIVE] Investigators. Poor achievement of guidelines-recommended targets in type 2 diabetes: findings from a contemporary prospective cohort study. Int J Clin Pract. 2012;66(5):457–464
   PubMedGoogle Scholar
• . Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AW, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122(5):443–453
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35( Suppl 1):S11–S63
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, ; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379
   PubMedGoogle Scholar
• . Rodbard HW, Jellinger PS, Davidson JA, . Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . Gerich JE. Physiology of glucose homeostasis. Diabetes Obes Metab. 2000;2(6):345–350
   PubMed Web of Science ®Google Scholar
• . Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008;62(8):1279–1284
   PubMed Web of Science ®Google Scholar
• . Mather A, Pollock C. Glucose handling by the kidney. Kidney Int Suppl. 2011;(120):S1–S6
   Google Scholar
• . Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136–142
   PubMed Web of Science ®Google Scholar
• . Shrayyef MZ, Gerich JE. Normal glucose homeostasis. In: Poretsky L, ed. Principles of Diabetes Mellitus. Berlin, Germany: Springer Science+Business Media, LLC; 2010:19–35
   Google Scholar
• . Meyer C, Dostou JM, Welle SL, Gerich JE. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab. 2002;282(2):E419–E427
   PubMed Web of Science ®Google Scholar
• . Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–794
   PubMed Web of Science ®Google Scholar
• . Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med. 2007;261(1):32–43
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Davidson JA, del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012;14(1):5–14
   PubMed Web of Science ®Google Scholar
• . Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest. 1998;102(3):619–624
   PubMed Web of Science ®Google Scholar
• . Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab. 2004;287(6):E1049–E1056
   PubMedGoogle Scholar
• . DeFronzo RA, Hompesch M, Kasichayanula S, . Renal glucose kinetics in response to dapagliflozin [abstract]. Diabetes. 2012;61( Suppl 1):A23–24. Abstract 83-OR
   PubMedGoogle Scholar
• . Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951;30(2):125–129
   PubMed Web of Science ®Google Scholar
• . Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54(12):3427–3434
   PubMed Web of Science ®Google Scholar
• . Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: a review. Diabetes Metab Res Rev. 2005;21(1):31–38
   PubMed Web of Science ®Google Scholar
• . Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–531
   PubMed Web of Science ®Google Scholar
• . Hardman TC, Dubrey SW. Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther. 2011;2(3):133–145
   PubMedGoogle Scholar
• . Katsuno K, Fujimori Y, Takemura Y, . Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther. 2007;320(1):323–330
   PubMed Web of Science ®Google Scholar
• . Devineni D, Morrow L, Hompesch M, . Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14(6):539–545
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Aggarwal N, Polidori D, ; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35(6):1232–1238
   PubMed Web of Science ®Google Scholar
• . Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010;95(1):34–42
   PubMed Web of Science ®Google Scholar
• . Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans? Diabetes. 2012;61(9):2199–2204
   PubMed Web of Science ®Google Scholar
• . Heise T, Seman L, Macha S, . Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus [published online ahead of print February 2013]. Diabetes Ther. doi: 10.1007/s13300–013–0030–2
   Google Scholar
• . Jabbour SA. The importance of reducing hyperglycemia while preserving insulin secretion—the rationale for sodium-coupled glucose co-transporter 2 inhibition in diabetes. US Endocrinology. 2009;5(1):75–78
   Google Scholar
• . Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495–502
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Iqbal N, T'joen C, List JF. Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14(10):951–959
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15(8):721–728
   PubMed Web of Science ®Google Scholar
• . Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33(10):2217–2224
   PubMed Web of Science ®Google Scholar
• . Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66(5):446–456
   PubMed Web of Science ®Google Scholar
• . Kadowaki T, Ikeda S, Takano Y, . Tofogliflozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and exercise alone [abstract]. Diabetes. 2012;61( Suppl 1):A22. Abstract 80-OR
   Web of Science ®Google Scholar
• . Kawano H, Kashiwagi A, Kazuta K, Yoshida S, Ueyama E, Utsuno A. Long-term safety, tolerability and efficacy of ipragliflozin in Japanese patients with type 2 diabetes mellitus: IGNITE [abstract]. Diabetes. 2012;61( Suppl 1):A611. Abstract 2422-PO
   Google Scholar
• . List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32(4):650–657
   PubMed Web of Science ®Google Scholar
• . Fonseca VA, Ferrannini E, Wilding JP, . Active- and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications. 2013;27(3):268–273
   PubMed Web of Science ®Google Scholar
• . Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13(12):1219–1227
   PubMed Web of Science ®Google Scholar
• . Seino Y, Sasaki T, Fukatsu A, Samukawa Y, Sakai S, Watanabe T. Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus [abstract]. Diabetes. 2012;61( Suppl 1):A266–267. Abstract 1039-P
   Web of Science ®Google Scholar
• . Stenlöf K, Cefalu WT, Kim KA, . Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382
   PubMed Web of Science ®Google Scholar
• . Woerle HJ, Ferrannini E, Berk A, . Long-term safety and efficacy of empagliflozin sitagliptin, and metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes [published online ahead of print November 1, 2013]. Diabetes Care. doi:10.2337/dc13–0663
   Google Scholar
• . Jabbour SA, Whaley J, Tirmenstein, . Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin. Postgrad Med. 2012;124(4):62–73
   PubMed Web of Science ®Google Scholar
• . Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375(9733):2223–2233
   PubMed Web of Science ®Google Scholar
• . Cefalu WT, Leiter LA, Niskanen L, . Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [abstract]. Diabetes. 2012;61( Suppl 1 A):LB10. Abstract 38-LB
   Google Scholar
• . Bolinder J, Ljunggren Ö, Kullberg J, . Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020–1031
   PubMed Web of Science ®Google Scholar
• . Goto K, Kashiwagi A, Kazuta K, Yoshida S, Ueyama E, Utsuno A. Ipragliflozin reduces A1c and body weight in type 2 diabetes patients who have inadequate glycemic control on metformin alone: ILLUMINATE study [abstract]. Diabetes. 2012;61( Suppl 1):A269. Abstract 1046-P
   Google Scholar
• . Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus [erratum in Clin Pharmacol Ther 2009;85(5):558]. Clin Pharmacol Ther. 2009;85(5):513–519
   PubMed Web of Science ®Google Scholar
• . Nauck MA, del Prato S, Meier JJ, . Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled non-inferiority trial. Diabetes Care. 2011;34(9):2015–2022
   PubMed Web of Science ®Google Scholar
• . Rosenstock J, Seman LJ, Jelaska A, . Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013;15(12):1154–1160
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15(5):403–409
   PubMed Web of Science ®Google Scholar
• . Gross JL, Schernthaner G, Fu M, . Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with sitagliptin in patients with type 2 diabetes on metformin plus sulfonylurea [abstract]. Diabetes. 2012;61( Suppl 1 A):LB13. Abstract 50-LB
   Google Scholar
• . Wilding JP, Mathieu C, Vercruysse F, Usiskin K, Deng L, Canovatchel W. Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU) [abstract]. Diabetes. 2012;61( Suppl 1):A262. Abstract 1022-P
   Web of Science ®Google Scholar
• . Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35(7):1473–1478
   PubMed Web of Science ®Google Scholar
• . Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2011;13(10):928–938
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Woo V, Soler NG, ; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156(6):405–415
   PubMed Web of Science ®Google Scholar
• . Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32(9):1656–1662
   PubMed Web of Science ®Google Scholar
• . Veltkamp SA, Van Dijk J, Krauwinkel WJJ, Smulders RA. The effect of renal impairment on the pharmacokinetics and urinary glucose excretion of the SGLT2 inhibitor ASP1941 in type 2 diabetes mellitus patients [abstract]. Diabetes. 2011;60( Suppl 1):A309. Abstract 1127-P
   Google Scholar
• . FDA briefing document. NDA 202293 Dapagliflozin tablets, 5 and 10 mg. Advisory committee meeting, July 19, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ucm262994.pdf. Accessed January 7, 2013
   Google Scholar
• . Yale JF, Bakris G, Xi L, . Canagliflozin (CANA), a sodium glucose co-transporter 2 (SGLT2) inhibitor, improves glycemia and is well tolerated in type 2 diabetes mellitus (T2DM) subjects with moderate renal impairment [abstract]. Diabetes. 2012;61( Suppl 1 A):LB11. Abstract 41-LB
   Google Scholar
• . Forxiga [summary of product characteristics]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_–_Product_Information/human/002322/WC500136026.pdf. Bristol-Myers Squibb, AstraZeneca. Accessed January 14, 2013
   Google Scholar
• . Invokana [full prescribing information]. http://www.janssenmd.com/pdf/invokana/PI-INVOKANA.pdf. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2013. Accessed July 1, 2013
   Google Scholar
• . Boehringer Ingelheim. Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin. http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/26_march_2013_empagliflozin.html. Accessed July 9, 2013
   Google Scholar
• . Ferrannini E. Sodium-glucose transporter-2 inhibition as an antidiabetic therapy. Nephrol Dial Transplant. 2010;25(7):2041–2043
   PubMed Web of Science ®Google Scholar
• . Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin Ther. 2012;34(8):1761–1771
   PubMed Web of Science ®Google Scholar
• . Santer R, Calado J. Familial renal glucosuria and SGLT2: from a Mendelian trait to a therapeutic target. Clin J Am Soc Nephrol. 2010;5(1):133–141
   PubMed Web of Science ®Google Scholar
• . Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173–1178
   PubMed Web of Science ®Google Scholar
• . Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Vulvovaginitis and balanitis in patients with diabetes treated with dapagliflozin. J Diabetes Complications. 2013;27(5):479–484
   PubMed Web of Science ®Google Scholar
• . Nicolle LE, Capuano G, Ways K, Usiskin K. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study. Curr Med Res Opin. 2012;28(7):1167–1171
   PubMed Web of Science ®Google Scholar
• . Bristol-Myers Squibb, AstraZeneca. Background document, dapagliflozin, BMS-512148, NDA 202293. Last update: June 13, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM262996.pdf. Accessed January 7, 2013
   Google Scholar